Display Settings:

Format

Send to:

Choose Destination
    Endocrinol Metab Clin North Am. 2009 Mar;38(1):207-22.

    Lipid management in patients who have HIV and are receiving HIV therapy.

    Source

    Bellevue Hospital Center, AIDS Clinical Trials Unit, New York University School of Medicine, 550 First Avenue, BCD 5 (Room 558), NY 10016, USA. judith.aberg@nyumc.org

    Abstract

    Dyslipidemia now is recognized as a significant potential adverse event in HIV-infected patients who are receiving antiretroviral therapy. HIV-infected persons who have hyperlipidemia should be managed similarly to those without HIV infection in accordance with the National Cholesterol Education Program. Providers must treat the HIV infection first; if dyslipidemia develops, patients should be prescribed lipid-lowering therapies or should consider modifying their current antiretroviral therapy, if indicated. Evidence for these two strategies is discussed.

    PMID:
    19217520
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2753589
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Fig.1

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk